The integration of affinity-optimized scFv domains and selective costimulatory motifs (CD28, 4-1BB, or OX40) allows precise modulation of activation thresholds, improving both efficacy and safety in antigen-diverse breast cancer subtypes. Here, TNFRSF4 is linked to breast carcinoma.